SCHEMBL1642043

SCHEMBL1642043

O=C(O)CNC(=O)c1c(O)c(C(=O)NC2CCCCC2)cn(C2CC2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 5/20 0.47
EGLN3 Q9H6Z9 2/20 0.47
OGFOD1 Q8N543 1/20 0.47
EGLN2 Q96KS0 1/20 0.47
HIF1AN Q9NWT6 1/20 0.47
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
GAA P10253 1/20 0.43
PPARG P37231 1/20 0.43
NCOA2 Q15596 1/20 0.43
BBOX1 O75936 1/20 0.41
ASPH Q12797 1/20 0.41
KDM8 Q8N371 1/20 0.41
CNR1 P21554 9/20 0.41
CNR2 P34972 9/20 0.41
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642747 0.98 EGLN1 (0.50) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1642791 0.98 EGLN1 (0.50) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1641138 0.98 EGLN1 (0.50) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1641882 0.97 EGLN1 (0.48) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1642369 0.84 EGLN1 (0.47) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1642337 0.83 EGLN1 (0.46) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1642935 0.83 EGLN3 (0.48) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1641586 0.83 EGLN3 (0.48) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1642486 0.83 EGLN1 (0.47) EGLN1EGLN3OGFOD1EGLN2HIF1AN
SCHEMBL1642253 0.82 NPC1 (0.50) EGLN1EGLN3OGFOD1EGLN2HIF1AN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 EGLN1 6/4885EGLN3 3/4885OGFOD1 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.